Sugi Predict

Sugi Predict / Compounds / SCHEMBL1810558

SCHEMBL1810558

SCHEMBL1810558

CCOC(=O)CCc1cc(O)ccc1-c1ccc(-c2cccc(C)c2)c(CO)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.50
▸ CYP4A11 Q02928 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.41
▸ GAA P10253 3/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ ALOX5 P09917 2/20 0.39
▸ PTGES O14684 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ GLA P06280 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38660533 1.00 CYP4F2 (0.50) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL38661151 0.90 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL1891542 0.90 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL1891888 0.90 CYP4F2 (0.42) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL38659422 0.90 CYP4F2 (0.42) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL1822788 0.87 CYP4F2 (0.48) CYP4F2CYP4A11ALDH1A1GAAFFAR1
SCHEMBL1895417 0.87 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL38660721 0.87 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL1888903 0.86 FFAR1 (0.51) ALDH1A1FFAR1FFAR4KDM4EMEN1
SCHEMBL38660429 0.86 CYP4F2 (0.39) CYP4F2CYP4A11ALDH1A1GAAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition UNIVERSITAT DE VALENCIA (ES) 2016-06-30 — — US claimed
EP-2496544-B1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN S L (SE) 2014-08-20 — — EP claimed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US claimed
WO-2011054530-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN, S.L. (ES) 2011-05-12 — — WO claimed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US claimed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition UNIVERSITAT DE VALENCIA (ES) 2016-06-30 — — US disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP4F2 1508/4885CYP4A11 1872/4885ALDH1A1 3689/4885
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP4F2 1508/4885CYP4A11 1872/4885ALDH1A1 3689/4885
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP4F2 1508/4885CYP4A11 1872/4885ALDH1A1 3689/4885
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition VIM, EPCAM, CDH1 CYP4F2 4402/4885CYP4A11 4691/4885ALDH1A1 1400/4885
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP4F2 1508/4885CYP4A11 1872/4885ALDH1A1 3689/4885
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP4F2 1508/4885CYP4A11 1872/4885ALDH1A1 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.